Park Susanna B, Goldstein David, Lin Cindy S-Y, Krishnan Arun V, Friedlander Michael L, Kiernan Matthew C
Prince of Wales Medical Research Institute, Barker St, Randwick, Sydney, New South Wales 2031.
J Clin Oncol. 2009 Mar 10;27(8):1243-9. doi: 10.1200/JCO.2008.19.3425. Epub 2009 Jan 21.
Neurotoxicity is becoming increasingly recognized as the major dose-limiting toxicity of oxaliplatin. Because the mechanism of oxaliplatin-induced neurotoxicity remains unclear, the present study investigated the potential of axonal excitability techniques in identifying pathophysiologic mechanisms and early markers of nerve dysfunction.
Measures of sensory axonal excitability were recorded before and after infusion over 88 treatment cycles in 25 patients with colorectal cancer, who received a total oxaliplatin dose of 766 +/- 56 mg/m(2). Neurologic assessment, clinical rating scales, and routine nerve conduction studies were performed.
By completion of treatment, 16% of patients had developed severe (grade 3) neurotoxicity, and oxaliplatin dose reduction or cessation as a result of neurotoxicity was required in 40% of patients. Changes in axonal excitability occurred after infusion and could be explained on the basis of alterations in axonal membrane sodium (Na+) channel function (refractoriness: 7.6% +/- 1.7% before infusion v 4.5% +/- 1.4% after infusion; P = .03; superexcitability: -22.8% +/- 0.8% before infusion v -20.1% +/- 1.1% after infusion; P = .0002). Changes became less pronounced in later treatment cycles, suggesting that chronic nerve dysfunction and sensory loss masked acute effects at higher cumulative doses. Importantly, patients who demonstrated reductions in superexcitability in early treatment were subsequently more likely to develop moderate to severe neurotoxicity. The findings suggest that the degree of acute nerve dysfunction may relate to the development of chronic neurotoxicity.
Sensory axonal excitability techniques may facilitate identification of Na+ channel dysfunction in oxaliplatin-induced neurotoxicity and thereby provide a method to identify patients at risk for neurotoxicity to target those most likely to benefit from future neuroprotective strategies.
神经毒性日益被认为是奥沙利铂的主要剂量限制性毒性。由于奥沙利铂诱导神经毒性的机制尚不清楚,本研究探讨了轴突兴奋性技术在识别神经功能障碍的病理生理机制和早期标志物方面的潜力。
在25例接受奥沙利铂总剂量为766±56mg/m²的结直肠癌患者的88个治疗周期中,记录了输注前后的感觉轴突兴奋性指标。进行了神经学评估、临床评分量表和常规神经传导研究。
治疗结束时,16%的患者出现了严重(3级)神经毒性,40%的患者因神经毒性需要减少奥沙利铂剂量或停药。输注后轴突兴奋性发生了变化,这可以基于轴突膜钠(Na+)通道功能的改变来解释(不应期:输注前为7.6%±1.7%,输注后为4.5%±1.4%;P = 0.03;超兴奋性:输注前为-22.8%±0.8%,输注后为-20.1%±1.1%;P = 0.0002)。在后续治疗周期中,变化变得不那么明显,这表明慢性神经功能障碍和感觉丧失掩盖了较高累积剂量下的急性效应。重要的是,在早期治疗中表现出超兴奋性降低的患者随后更有可能发展为中度至重度神经毒性。这些发现表明,急性神经功能障碍的程度可能与慢性神经毒性的发展有关。
感觉轴突兴奋性技术可能有助于识别奥沙利铂诱导的神经毒性中的Na+通道功能障碍,从而提供一种方法来识别有神经毒性风险的患者,以便针对那些最有可能从未来神经保护策略中获益的患者。